読み込み中
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
前日終値
$1.11
+$0.06 · +5.71%
市場前
$1.1497
+$0.0397 · +3.58%
10月12日 9:01 ET
日中の時刻はETです。市場データは遅延する場合があります。
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
日中レンジ
現在 $1.11
52週レンジ
現在 $1.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
90
大幅な割安
センチメント
55
まちまち
リスク
75
高リスク
モメンタム
28
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
日中レンジ
現在 $1.11
52週レンジ
現在 $1.11
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8027.5万 USD | 6930万 USD | 5845.3万 USD | 4141.8万 USD | 2946.3万 USD |
| 売上原価 | 2593.4万 USD | 2281.2万 USD | 1834.1万 USD | 1437.4万 USD | 1065万 USD |
| 粗利益 | 5434.1万 USD | 4648.8万 USD | 4011.2万 USD | 2704.4万 USD | 1881.3万 USD |
| 研究開発 | 922万 USD | 881.3万 USD | 961.9万 USD | 893.7万 USD | 674.3万 USD |
| 販売・一般管理 | 7887.6万 USD | 7937万 USD | 7456.8万 USD | 5711.4万 USD | 4152.1万 USD |
| 営業費用 | 8809.6万 USD | 8060.3万 USD | 8418.7万 USD | 6605.1万 USD | 4826.4万 USD |
| 支払利息 | 524.5万 USD | 529万 USD | 522.3万 USD | 405.1万 USD | 359.7万 USD |
| 減価償却費と償却費 | 101万 USD | 101.2万 USD | 80.8万 USD | 118.7万 USD | 53.5万 USD |
| 営業利益 | −3375.5万 USD | −3411.5万 USD | −4407.5万 USD | −3900.7万 USD | −2945.1万 USD |
| 純利益 | −3883.1万 USD | −3784.1万 USD | −4666.4万 USD | −4429.6万 USD | −3327.6万 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.00
上昇余地（80.18%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
